1. Adesoye T, Lucci A. Current surgical management of inflammatory breast cancer. Ann Surg Oncol. 2021;28(10):5461–7.
2. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: the University of Texas MD Anderson Cancer Center experience. J Clin Oncol. 2001;19(3):628–33.
3. Fouad TM, Barrera AM, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V. Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system. Lancet Oncol. 2017;18(4):e228–32.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 5.2021—June 28, 2021. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 July 2021
5. Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. IJROBP. 2008;72(2):474–84.